SIC
INO icon

SJS Investment Consulting’s Inovio Pharmaceuticals INO Stock Holding History

SJS Investment Consulting’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$0 Buy
+1
New +$45 ﹤0.01% 1010

Other funds holding INO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SJS Investment Consulting's INO Position: Q1 2022 in Review

SJS Investment Consulting opened a new position in Inovio Pharmaceuticals (INO) in Q1 2022: 1 share worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1010 among its holdings.

198 funds tracked by Wall St. Rank hold INO as of Q1 2022.

  • SJS Investment Consulting held 1 share of Inovio Pharmaceuticals worth $0 as of Q1 2022.
  • Inovio Pharmaceuticals was a new SJS Investment Consulting position in Q1 2022.
  • Inovio Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q1 2022, its #1010 holding.
  • 198 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2022.

Based on SJS Investment Consulting's 13F filing for Q1 2022, filed 5 May 2022.